DGIdb - ARIPIPRAZOLE Drug Record

ARIPIPRAZOLE chembl:CHEMBL1112 Approved

Alternate Names:

OPC-31
OPC-14597
ARIPIPRAZOLE
ABILIFY MAINTENA
ABILIFY MYCITE KIT
ABILIFY MAINTENA KIT
ABILIFY
ARIPIPREX
OPC 14597
ABILITAT
OPC 31
ARIPIPRAZOL
ARIPIPRAZOLUM
pubchem.compound:60795
chembl:CHEMBL1112
rxcui:89013
drugbank:01238
chemidplus:129722-12-9

Drug Info:

Drug Class	antipsychotic agents
Year of Approval	2002
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antipsychotic agent

(3 More Sources)

Publications:

Inoue et al., 1997, Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum., Eur. J. Pharmacol.
Wood et al., 2007, Aripiprazole acts as a selective dopamine D2 receptor partial agonist., Expert Opin Investig Drugs
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Hirose et al., 2005, Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist., J. Med. Invest.
Wood et al., 2006, Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties., Eur. J. Pharmacol.
Kim et al., 2006, Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study., Hum Psychopharmacol
Arranz MJ et al., 1998, Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response., Pharmacogenetics
Eum S et al., 2017, Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report., BMC Psychiatry
Zhang JP et al., 2010, D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis., Am J Psychiatry
Lawler CP et al., 1999, Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes., Neuropsychopharmacology
Batra S, 1976, Unconjugated estradiol in the myometrium of pregnancy., Endocrinology
Ohara K et al., 1998, Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia., Psychiatry Res
Li T et al., 1998, Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia., Schizophr Res
Huertas E et al., 2010, The D2 dopamine receptor gene variant C957T affects human fear conditioning and aversive priming., Genes Brain Behav
Hirvonen MM et al., 2009, C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity., Synapse
Betcheva ET et al., 2009, Case-control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian population., J Hum Genet
Shen YC et al., 2009, Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients., J Psychiatr Res
Crettol S et al., 2008, Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment., Prog Neuropsychopharmacol Biol Psychiatry
Allen NC et al., 2008, Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database., Nat Genet
Xing Q et al., 2007, The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients., Int J Neuropsychopharmacol
Hoenicka J et al., 2006, C957T DRD2 polymorphism is associated with schizophrenia in Spanish patients., Acta Psychiatr Scand
Hänninen K et al., 2006, Association between the C957T polymorphism of the dopamine D2 receptor gene and schizophrenia., Neurosci Lett
Lencz et al., 2006, DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients., Am J Psychiatry
Lerman C et al., 2006, Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials., Neuropsychopharmacology
Hwang R et al., 2005, Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations., Psychopharmacology (Berl)
Wu et al., 2005, Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients., Neurosci. Lett.
Lawford BR et al., 2005, The C/C genotype of the C957T polymorphism of the dopamine D2 receptor is associated with schizophrenia., Schizophr Res
Yamanouchi Y et al., 2003, Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone., Pharmacogenomics J
Li T et al., 2002, Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A)gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects., Am J Med Genet
Suzuki A et al., 2001, The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients., Pharmacogenetics
de Bartolomeis A et al., 2015, Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism., CNS Drugs
Marona-Lewicka et al., 2004, Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats., Psychopharmacology (Berl.)
Cosi et al., 2005, Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation., Brain Res.
Jordan et al., 2002, The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor., Eur. J. Pharmacol.
Jordan et al., 2004, In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function., Eur. J. Pharmacol.
Swainston Harrison et al., 2004, Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder., Drugs
Stark et al., 2007, Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies., Psychopharmacology (Berl.)
Bortolozzi et al., 2007, In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain., Psychopharmacology (Berl.)
Meltzer et al., 2003, Serotonin receptors: their key role in drugs to treat schizophrenia., Prog. Neuropsychopharmacol. Biol. Psychiatry
Serretti A et al., 2009, Influence of TAAR6 polymorphisms on response to aripiprazole., Prog Neuropsychopharmacol Biol Psychiatry
Zhang JP et al., 2016, Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis., Schizophr Bull
Czerwensky F et al., 2013, MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?, Int J Neuropsychopharmacol
Nurmi EL et al., 2013, Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies., Transl Psychiatry
Malhotra AK et al., 2012, Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain., Arch Gen Psychiatry
Wang R et al., 2018, ABCB1 1199G > A Polymorphism Impacts Transport Ability of P-gp-Mediated Antipsychotics., DNA Cell Biol
Monteleone P et al., 2010, Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain., J Clin Psychopharmacol
Tiwari AK et al., 2010, A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia., Neuropsychopharmacology
Delacrétaz A et al., 2017, Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs., Gene
Ikeda M et al., 2008, Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia., Pharmacogenomics

ARIPIPRAZOLE TAAR6

Interaction Score: 10.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19345712

Sources:
PharmGKB
ARIPIPRAZOLE MC4R

Interaction Score: 1.61

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27217270 23920449 23799528 22566560

Sources:
PharmGKB
ARIPIPRAZOLE ANKK1

Interaction Score: 1.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18926547 18855532

Sources:
PharmGKB
ARIPIPRAZOLE RABEP1

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28694205

Sources:
PharmGKB
ARIPIPRAZOLE SH2B1

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28694205

Sources:
PharmGKB
ARIPIPRAZOLE DRD2

Interaction Score: 1.12

Interaction Types & Directionality:

partial agonist (activating)

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Trial Name Abilify

Novel drug target Established target

Mechanism of Interaction Dopamine D2 receptor partial agonist

PMIDs:
9083792 17501690 11752352 16366516 16925992 16981227 9918131 28673279 20194480 10327430 991813 9858029 9713903 19900188 19582781 19158809 18926547 18687376 18583979 17105675 17087792 16973280 16513877 16123753 15830237 15694263 15567074 14610521 11920858 11505224 26346901

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD
ARIPIPRAZOLE HTR1A

Interaction Score: 0.83

Interaction Types & Directionality:

partial agonist (activating)

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Serotonin 1a (5-HT1a) receptor partial agonist

Trial Name Abilify

PMIDs:
14647959 15862515 12063084 14709325 15257633 26346901

Sources:
TdgClinicalTrial ChemblInteractions TEND
ARIPIPRAZOLE CNR1

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23799528 20631561 20107430

Sources:
PharmGKB
ARIPIPRAZOLE FAAH

Interaction Score: 0.49

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20631561

Sources:
PharmGKB
ARIPIPRAZOLE HTR2A

Interaction Score: 0.36

Interaction Types & Directionality:

partial agonist (activating)

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Serotonin 2a (5-HT2a) receptor antagonist

Trial Name Abilify

PMIDs:
17242925 17265076 14642974 26346901

Sources:
TdgClinicalTrial ChemblInteractions TEND
ARIPIPRAZOLE ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29443543

Sources:
PharmGKB
ARIPIPRAZOLE CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
FDA

TEND: ARIPIPRAZOLE
- Version: 01-August-2011
Alternate Names:

ARIPIPRAZOLE Primary Drug Name

Drug Info:

Year of Approval 2002

Drug Class antipsychotic agents

Publications:
TdgClinicalTrial: ARIPIPRAZOLE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antipsychotic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

PharmGKB: aripiprazole

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Li T et al., 1998, Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia., Schizophr Res

Wu et al., 2005, Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients., Neurosci. Lett.

Eum S et al., 2017, Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report., BMC Psychiatry

TTD: Aripiprazole
- Version: 2020.06.01
Alternate Names:

D0H3HM TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL1112
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1112
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Aripiprazole
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Trial Name	Abilify
Novel drug target	Established target
Mechanism of Interaction	Dopamine D2 receptor partial agonist

Direct Interaction	yes
Mechanism of Interaction	Serotonin 1a (5-HT1a) receptor partial agonist
Trial Name	Abilify

Direct Interaction	yes
Mechanism of Interaction	Serotonin 2a (5-HT2a) receptor antagonist
Trial Name	Abilify

ARIPIPRAZOLE Drug Record

ARIPIPRAZOLE chembl:CHEMBL1112 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19345712

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27217270 23920449 23799528 22566560

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18926547 18855532

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28694205

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28694205

Sources: PharmGKB

Interaction Types & Directionality: partial agonist (activating) agonist (activating) antagonist (inhibitory)

Interaction Info: Trial Name Abilify Novel drug target Established target Mechanism of Interaction Dopamine D2 receptor partial agonist

PMIDs: 9083792 17501690 11752352 16366516 16925992 16981227 9918131 28673279 20194480 10327430 991813 9858029 9713903 19900188 19582781 19158809 18926547 18687376 18583979 17105675 17087792 16973280 16513877 16123753 15830237 15694263 15567074 14610521 11920858 11505224 26346901

Sources: TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality: partial agonist (activating) agonist (activating) antagonist (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Serotonin 1a (5-HT1a) receptor partial agonist Trial Name Abilify

PMIDs: 14647959 15862515 12063084 14709325 15257633 26346901

Sources: TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23799528 20631561 20107430

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20631561

Sources: PharmGKB

Interaction Types & Directionality: partial agonist (activating) agonist (activating) antagonist (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Serotonin 2a (5-HT2a) receptor antagonist Trial Name Abilify

PMIDs: 17242925 17265076 14642974 26346901

Sources: TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29443543

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: FDA

TEND: ARIPIPRAZOLE

Alternate Names: ARIPIPRAZOLE Primary Drug Name

Drug Info: Year of Approval 2002 Drug Class antipsychotic agents

Publications:

TdgClinicalTrial: ARIPIPRAZOLE

Alternate Names:

Drug Info: Drug Indications antipsychotic agent Drug Class Small Molecule FDA Approval approved

Publications:

PharmGKB: aripiprazole

Alternate Names:

Drug Info:

TTD: Aripiprazole

Alternate Names: D0H3HM TTD Drug ID

Drug Info:

Publications:

ChemblInteractions: CHEMBL1112

Alternate Names:

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1112

Alternate Names:

Drug Info:

Publications:

FDA: Aripiprazole

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
19345712

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27217270 23920449 23799528 22566560

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18926547 18855532

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28694205

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28694205

Sources:
PharmGKB

Interaction Types & Directionality:

partial agonist (activating)

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Trial Name Abilify

Novel drug target Established target

Mechanism of Interaction Dopamine D2 receptor partial agonist

PMIDs:
9083792 17501690 11752352 16366516 16925992 16981227 9918131 28673279 20194480 10327430 991813 9858029 9713903 19900188 19582781 19158809 18926547 18687376 18583979 17105675 17087792 16973280 16513877 16123753 15830237 15694263 15567074 14610521 11920858 11505224 26346901

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality:

partial agonist (activating)

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Serotonin 1a (5-HT1a) receptor partial agonist

Trial Name Abilify

PMIDs:
14647959 15862515 12063084 14709325 15257633 26346901

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

n/a

PMIDs:
23799528 20631561 20107430

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20631561

Sources:
PharmGKB

Interaction Types & Directionality:

partial agonist (activating)

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Serotonin 2a (5-HT2a) receptor antagonist

Trial Name Abilify

PMIDs:
17242925 17265076 14642974 26346901

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

n/a

PMIDs:
29443543

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
FDA

Alternate Names:

ARIPIPRAZOLE Primary Drug Name

Drug Info:

Year of Approval 2002

Drug Class antipsychotic agents

Drug Info:

Drug Indications antipsychotic agent

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

D0H3HM TTD Drug ID